Efficacy and Safety of AAE581 in Postmenopausal Women With Osteopenia/Osteoporosis.
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
AAE581 is a specific inhibitor of the cysteine protease cathepsin K. This trial is designed
to provide detailed information about the effects( efficacy and safety) of AAE581 on Bone
Mineral Density.